恶性淋巴瘤患儿血清血管内皮生长因子的表达及临床意义

The expression of vascular endothelial growth factor in children with non-Hodgkin’s lymphoma and its clinical significance

目的探讨恶性淋巴瘤患儿血清血管内皮生长因子(VEGF)水平与淋巴瘤的发生、分期及复发之间的关系。方法采用酶联免疫吸附法(ELISA)对48例儿童恶性淋巴瘤患者治疗前后及33例健康体检者(对照组)进行VEGF测定。结果初发及复发的恶性淋巴瘤患儿VEGF高于对照组水平(P<0.01);Ⅲ、Ⅳ期高于Ⅰ、Ⅱ期患儿(P<0.01);缓解者较治疗前明显降低(P<0.01);B组高于A组(P<0.01);HL与NHL的VEGF表达差异无显著性(P>0.05)。结论动态监测VEGF对儿童恶性淋巴瘤患者的辅助诊断、疗效评定及预后判断有一定的指导意义。

Objective To determine the serum vascular endothelial growth factor （VEGF） level in children with non-Hodgkin＇s lymphoma （NHL） and elucidate the relationship between its level and the development, the stages, and the relapse of the NHL. Methods Serum VEGF levels were measured in 48 children with non-Hodgkin＇ s lymphoma （group A） before and after treatment by sandwich ELISA, and the 33 healthy individuals in group B. Results The VEGF levels in the patients with newly diagnosed,or relapsed, and no remitted lymphoma were significantly higher than those in normal controls （P〈0.01） . It was significantly higher in the patients of stage Ⅲ, Ⅳ than the patients in stage Ⅰ, Ⅱ . And also significantly higher in group B in comparison with group A. But significantly lower in the patients with complete remission and partial remission in comparison with the newly diagnosed patients. No marked difference was found between Hodgkin＇ s lymphoma （HL） and NHL, Conclusions Dynamic changes of VEGF level can be used as the alternate index in diagnosing patients, assessing therapeutic effect and predicting the prognosis of non-Hodgkin＇ s lymphoma.